Integrative Management and Treatment Options for Neuropathic Pain

Find out how integrative management of neuropathic pain can provide holistic solutions for effective pain management.

Abstract

Hello, I’m Dr. Alex Jimenez. Welcome to our educational series, where we explore complex health challenges through the lens of integrative and functional medicine. This post presents a detailed journey into managing complex, severe neuropathic pain, particularly when conventional methods fall short. We will follow a challenging patient case to illustrate the nuanced strategies of opioid rotation, dose titration, the critical identification of opioid-induced hyperalgesia (OIH), and advanced therapies like methadone and intrathecal pain pumps. You will learn about the physiological mechanisms behind these concepts, their clinical presentation, and evidence-based strategies to overcome them.

A central theme will be the power of a multidisciplinary, integrative approach that combines advanced interventional pain management with chiropractic care and regenerative therapies such as ultrasound-guided Platelet-Rich Plasma (PRP) injections. This showcases how our team at Injury Medical Clinic PA in El Paso, Texas, collaborates to provide comprehensive care. This collaboration is a cornerstone of our practice, where I, as a Doctor of Chiropractic with extensive training in functional medicine, work alongside our esteemed Medical Director, Dr. Maria Guadalupe Cardenas, a Board-Certified Internist with over four decades of experience. Together, we integrate chiropractic care, medical oversight, functional medicine, regenerative orthobiologics, personal injury care, and rehabilitation to create a holistic treatment plan tailored to each patient’s unique needs. This comprehensive guide presents the latest findings from leading researchers, demonstrating how an integrative model provides a holistic framework for treating our most complex patients.

Our Integrative Practice: A Collaborative Model of Care

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, our philosophy is rooted in the belief that comprehensive healing requires a team-based, integrative approach. This model is brought to life through the unique partnership between me, Dr. Alex Jimenez, and our Medical Director, Dr. Maria Guadalupe Cardenas. My background as a Doctor of Chiropractic (DC) is complemented by advanced credentials, including Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), Certified Functional Medicine Practitioner (CFMP), and Institute for Functional Medicine Certified Practitioner (IFMCP), among others. This diverse training allows me to view patient health through a multifaceted lens, focusing on biomechanics, nervous system function, and the underlying physiological imbalances that drive chronic pain.

Dr. Cardenas, with her extensive 40-year career as a Board-Certified Internist (NPI #1164426749, Texas MD License #J2933), provides the essential medical oversight and direction for our practice. Her profound experience in internal medicine is invaluable, particularly in complex cases involving pharmacological management, systemic factors, and acute medical issues. This collaborative structure, in which an MD provides medical direction alongside a chiropractor, is common in leading-edge integrative and injury-care clinics. It ensures that our patients receive a full spectrum of care that is both safe and effective.

Together, our team integrates:

• Integrative Chiropractic Care: I focus on restoring spinal and joint function, which is often a primary or contributing factor to pain. By addressing biomechanical imbalances, we can reduce nerve irritation and improve the body’s structural foundation, which is crucial for long-term pain relief.
• Medical Oversight (Internal Medicine): Dr. Cardenas provides diagnoses, prescribes necessary medications like opioids when appropriate, and oversees the medical aspects of patient care, ensuring safety and efficacy.
• Functional Medicine: We delve into the root causes of dysfunction, examining genetics, lifestyle, environment, nutrition, and inflammation to understand why a patient experiences chronic neuropathic pain.
• Regenerative Medicine & PRP Therapy: We utilize ultrasound-guided Platelet-Rich Plasma (PRP) injections and other orthobiologics to deliver concentrated growth factors directly to irritated nerves and surrounding tissues. This promotes nerve repair, reduces neuroinflammation, and supports healing in areas of chronic irritation or post-procedural scarring—complementing both pharmacological and chiropractic interventions.
• Personal Injury Care & Rehabilitation: Our team is skilled in managing acute injuries and guiding patients through comprehensive rehabilitation programs to restore function and prevent long-term disability.

This case study perfectly illustrates how these disciplines converge to solve a complex clinical puzzle, offering hope and healing where conventional, siloed approaches might fall short.

Initial Presentation: A Patient in Distress

Let’s begin by introducing the patient at the heart of this discussion, whom we will call DM. She is a 70-year-old female who presented with a complex medical history and a significant pain crisis.

Patient Background:

• History: She had a prior episode of shingles that resulted in postherpetic neuralgia. She presented with a right-sided pleural effusion that required drainage.
• Recent Procedure: She underwent a thoracentesis to drain the fluid, but this was complicated by a pneumothorax (collapsed lung), requiring the insertion of a chest tube.
• Admission: Due to the complication and significant pain, she was admitted to the hospital for observation and care.
• Pain Profile: She reported not only acute pain at the chest tube site but also a worsening of chronic, right-sided neuropathic pain that she described as originating from her prior postherpetic neuralgia.

Social and Family History:

• She was married with no children.
• A former smoker with infrequent alcohol use and no illicit substance use.
• Her family history included significant respiratory illnesses.

Upon my initial examination, DM appeared thin and chronically ill. Her vital signs were stable, but the physical exam revealed several key findings:

• Pulmonary: Decreased breath sounds on the right side, consistent with her recent pneumothorax.
• Musculoskeletal: Extreme tenderness to even light touch over the lower right chest and back. This sensitivity followed a clear dermatomal pattern, specifically along the T4-T8 thoracic nerve roots. A dermatome is an area of skin primarily supplied by a single spinal nerve, and pain that follows this pattern is a classic sign of nerve involvement.
• Labs: Blood work was notable for hypoalbuminemia (low protein levels, often seen in chronic illness and malnutrition), hypomagnesemia (low magnesium), and mild leukocytosis (elevated white blood cells, suggesting inflammation).

Our integrative pain management team was consulted on her eighth day in the hospital. By this time, she had already endured a week of escalating pain and medical interventions, including a VATS (Video-Assisted Thoracoscopic Surgery) procedure with pleural evaluation on day seven.

A Thorough Pain Assessment: Uncovering the Neuropathic Signature

When our team first met DM, her chest tube had thankfully been removed, but the sutures were still in place. The site of the former chest tube and the VATS procedure coincided exactly with the area of her neuropathic discomfort. Her description of the pain was strikingly vivid and clinically significant. She described it as a sensation of “a thousand stinging electric shocks” in the T4-T8 dermatomal distribution. This language is a hallmark of neuropathic pain—pain originating from damage or dysfunction of the nervous system itself, as opposed to pure nociceptive pain from tissue injury.

To fully understand her experience, we employed the PQRSTU algorithm, a comprehensive framework for pain assessment.

• P (Precipitating/Palliating/Previous Treatment): Her pain was continuous. Nothing seemed to make it better or worse. It had begun a few months prior, in December 2024, diagnosed as postherpetic neuralgia (nerve pain after shingles), although she interestingly never had the characteristic rash. She had tried gabapentin previously but stopped it due to a lack of efficacy and worsening bilateral lower extremity edema (swelling).
• Q (Quality): As mentioned, she described it as severe, stinging, electric shocks.
• R (Region/Radiation): The pain was confined to the right-sided T4-T8 dermatome, with no radiation. It was exquisitely tender to both light touch (allodynia) and deep palpation (hyperalgesia).
• S (Severity): She rated her pain as a 5-7 out of 10. Her current pain was a 5/10, and she identified a tolerable level as a 3/10. Establishing a realistic, tolerable pain level is a critical part of a functional approach to pain management. Our goal isn’t always zero pain, but rather to restore function and quality of life.
• T (Temporal Aspects): At the time of our consultation, she was on a Dilaudid (hydromorphone) PCA (Patient-Controlled Analgesia) pump, which was started after her VATS procedure. It provided temporary relief, but she would fall asleep only to be awakened by severe pain 30-45 minutes later as the medication wore off. This cyclical pattern of relief and rebound pain is common and indicates that the underlying pain mechanism is not being adequately addressed.
• U (Impact on You): The pain was devastating to her quality of life. She reported being unable to concentrate, ambulate, eat, or even consider returning home.

Her current medication regimen at the time of our consult included the Dilaudid PCA, her home dose of long-acting morphine (MS Contin 15 mg twice daily), and as-needed oxycodone, Toradol (an IV anti-inflammatory), and medications for nausea and constipation.

Movement Medicine: Chiropractic Care- Video

Strategizing the Initial Treatment: Targeting the Nerves

Given the clear neuropathic signature of her pain, my primary focus was to introduce an adjuvant medication specifically designed to target nerve pain. Opioids, while helpful for nociceptive pain, are often less effective for neuropathic pain and can contribute to side effects like sedation and confusion, which she was already experiencing.

Understanding Neuropathic Pain Medications

Neuropathic pain can stem from central or peripheral nervous system dysfunction. We tailor our medication choices accordingly:

• Central Etiologies: These are often managed with antiepileptic drugs (AEDs) like gabapentin, pregabalin, carbamazepine, and oxcarbazepine. These medications work by calming hyperexcitable neurons in the central nervous system.
• Peripheral Etiologies: For these, we often turn to SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) such as duloxetine and venlafaxine, or TCAs (Tricyclic Antidepressants) such as amitriptyline and nortriptyline. These drugs modulate neurotransmitters involved in pain signaling pathways.
• Localized Pain: Topical agents like capsaicin or lidocaine patches can be effective when the pain is confined to a small area.
• Complex Mixed Pain: In refractory cases with both nociceptive and neuropathic components plus central sensitization, methadone can be a powerful option. It is unique among opioids due to its additional action as an NMDA receptor antagonist, which helps to combat central sensitization and hyperalgesia.

When selecting a medication, I consider the patient’s symptoms, potential side effects that could be beneficial (e.g., using a sedating medication at night for a patient with insomnia), comorbidities, and other medications. We also consider regenerative options, such as PRP, to address peripheral drivers of nerve irritation.

Our Initial Plan

Based on this framework, we implemented the following changes:

1. Initiate Pregabalin (Lyrica): We started pregabalin at a very low dose of 25 mg, taken three times daily. Although she had a poor experience with gabapentin, pregabalin has a different pharmacokinetic profile that can sometimes be better tolerated. We chose a low dose to mitigate the risk of worsening her lower extremity edema. The plan was to titrate the dose up slowly as tolerated.
2. Optimize Non-Opioid Analgesia: We discontinued the as-needed oxycodone/acetaminophen combo and instead scheduled acetaminophen 1000 mg every eight hours. Scheduled dosing provides a stable analgesic foundation, which is far more effective for managing chronic pain than chasing it with PRN (as-needed) doses.
3. Continue Foundational Opioids: We continued her long-acting MS Contin and encouraged her to use the Dilaudid PCA as needed. At this stage, I wanted to understand the total amount of opioid she required to achieve comfort after we added the neuropathic agent.
4. Introduce a Multidisciplinary Team: This is where the integrative model truly shines. We brought in our supportive care chaplain and our licensed clinical social worker. Pain is not just a physical sensation; it has profound emotional, spiritual, and psychological dimensions. Our social worker provided her with coping mechanisms, while the chaplain offered spiritual support to help her manage the immense stress of her illness and pain. This holistic approach is fundamental to our practice at Injury Medical Clinic PA, where we recognize that healing involves the entire person. We also began planning for regenerative interventions once acute issues stabilized.

A Complicated Course: Navigating Setbacks and Team Dynamics

Unfortunately, DM’s journey was not a straight line to recovery. While her pain initially improved slightly, she soon developed dizziness, intermittent confusion, and mild resting tremors. We suspected the pregabalin was the cause and discontinued it, switching to a low dose of amitriptyline, a TCA that can also be effective for neuropathic pain.

This is where a common challenge in hospital-based care emerged. The primary medical team, concerned about the new neurological symptoms, consulted neurology. The neurologist, not having seen our team’s note about the adverse reaction to pregabalin, switched her back to it and added lidocaine patches. This highlights the critical importance of clear inter-team communication in complex cases.

Simultaneously, the Dilaudid PCA was discontinued per hospital protocol, and she was transitioned to as-needed IV hydromorphone. The result was a perfect storm:

• The tremors and confusion returned upon reinitiation of pregabalin.
• Her pain escalated because the intermittent, as-needed IV opioid was not providing the steady relief the PCA had.
• She developed insomnia, and her oral intake worsened.

Amid this chaos, we finally received the pathology report from her pleural evaluation, which revealed chronic inflammatory and fibrotic changes consistent with the effects of the prior procedures and prolonged pleural irritation. This helped confirm that the pain was primarily driven by neuropathic mechanisms from the longstanding postherpetic neuralgia, now significantly exacerbated by mechanical trauma and nerve irritation from the chest tube and VATS sites in the T4-T8 region. This new information demanded a re-evaluation of our entire strategy.

Recognizing Opioid-Induced Hyperalgesia (OIH)

This scenario is the perfect entry point to discuss a poorly recognized but surprisingly common side effect of opioids: opioid-induced hyperalgesia (OIH). Most clinicians are familiar with common opioid side effects like drowsiness, constipation, and nausea. But OIH, a paradoxical increase in pain sensitivity caused by the opioids themselves, is often missed.

The Pathophysiology of OIH

OIH is a true neurotoxic side effect. Here’s a breakdown of what happens in the nervous system:

• Buildup of Toxic Metabolites: Over time, especially at higher doses, opioids break down into toxic metabolites. Morphine and hydromorphone are particularly known for this. Some individuals are genetically more susceptible to this buildup.
• Central Sensitization via NMDA Receptors: These toxic metabolites lead to central sensitization, a state of nervous system hyperexcitability. A key mechanism is the activation of NMDA receptors in the central nervous system (Lee et al., 2011). This is ironic, as we sometimes use NMDA receptor antagonists to treat pain.
• Neurochemical Cascade: This activation triggers a cascade of events, including increased spinal dynorphin activity, descending facilitation from the rostral ventromedial medulla, and increased activation of intracellular protein kinase C.

Essentially, the very drug meant to relieve pain starts rewiring the nervous system to become more sensitive to pain.

The Clinical Picture of OIH

How can you spot OIH in your patients? Look for this constellation of signs:

• Hyperexcitability: The earliest signs can be subtle. Think of myoclonus (muscle twitching or jerking), restlessness, and an inability to get comfortable.
• Worsening and Spreading Pain: This is the hallmark. The patient reports that despite increasing opioid doses, their pain is getting worse, not better. The pain may also spread beyond the original site, becoming more diffuse.
• Allodynia: This is a classic sign where non-painful stimuli become painful. The light touch of a bedsheet, the pressure of a blood pressure cuff, or a gentle stroke on the arm can cause significant pain. This is a definitive indicator that the nervous system is hypersensitive.
• End-Stage Neurotoxicity: As the toxic metabolites accumulate, the symptoms can escalate to delirium, hallucinations (as our patient experienced), and, if left untreated, even seizures.

When you have a patient on opioids whose pain is escalating without a clear cause, and higher doses are not providing relief, you must consider OIH. The instinct might be to stop the opioids, but that can cause severe withdrawal and uncontrolled pain. A more strategic approach is needed.

Re-Strategizing with Opioid Rotation and Advanced Calculations

With the confirmation of the chronic neuropathic and post-procedural drivers and her current regimen failing, it was time for a significant change. Her pain was inadequately controlled, and she was suffering from opioid-related neurotoxicity (confusion, tremors). This is a classic indication for opioid rotation—the process of switching from one opioid to another to improve the balance between analgesia (pain relief) and adverse effects.

The Principles of Opioid Rotation

The rationale behind opioid rotation is based on the concept of incomplete cross-tolerance. An individual who has developed tolerance to one opioid will not have the same level of tolerance to another. As Pasternak (2010) notes, while most opioids act on mu-opioid receptors, they interact with different subsets of these receptors in unique ways. By switching, we can often achieve better pain control at a lower equianalgesic dose, thereby reducing side effects.

The process requires careful calculation of the Morphine Milligram Equivalent (MME) or Oral Morphine Equivalency (OME). This is a standardized measure used to compare the potencies of different opioids. Everything is converted to a baseline equivalent of oral morphine.

Key Conversion Ratios (Oral Morphine as Baseline):

• Oxycodone: 1.5 times more potent than oral morphine (10 mg oral morphine = 6.7 mg oxycodone).
• Hydrocodone: Roughly equivalent to oral morphine (1:1 ratio).
• Hydromorphone (Dilaudid): Oral hydromorphone is about 4 times more potent than oral morphine. IV hydromorphone is significantly more potent. The conversion from IV hydromorphone to oral morphine is approximately 1:20 (1 mg IV hydromorphone = 20 mg oral morphine).

Calculating the Total Daily Dose

To rotate a patient, we first calculate their total 24-hour opioid consumption in MME. For example, a patient using:

• IV Hydromorphone: 0.5 mg x 4 doses = 2 mg total. (2 mg IV hydromorphone x 20 = 40 MME)
• Oral Oxycodone: 10 mg x 5 doses = 50 mg total. (50 mg oxycodone x 1.5 = 75 MME)
• Oral Morphine: 15 mg x 2 doses = 30 mg total. (30 mg morphine x 1 = 30 MME)
• Total Daily MME: 40 + 75 + 30 = 145 MME

When switching to a new opioid, we typically reduce the calculated equianalgesic dose by 25-50%. This reduction accounts for incomplete cross-tolerance and is a critical safety measure to prevent accidental overdose (Webster & Fine, 2012). The size of the reduction depends on the patient’s age, organ function, and the reason for the rotation. For a patient with neurotoxicity, a more significant reduction (e.g., 50%) is often warranted.

For DM, her pain was now understood to be a complex mix of:

1. Nociceptive Pain: From the procedural sites (chest tube, VATS trauma).
2. Neuropathic Pain: From the chronic postherpetic neuralgia, now exacerbated by nerve irritation and scarring from the thoracic procedures.
3. Opioid-Induced Neurotoxicity: Contributing to her confusion and tremors.

The best strategy for OIH is to perform an opioid rotation, maximize non-opioid adjuvant medications, and incorporate regenerative therapies like PRP to address peripheral nerve and tissue drivers. By switching to a different opioid, we can give the specific subset of mu-receptors that were being overstimulated a break while engaging a new set. This is a technique I often use in my chronic pain patients, sometimes rotating them between hydrocodone and oxycodone to prevent tolerance and hyperalgesia from developing.

Let’s return to our patient. By day 14 in the hospital, her pain began escalating again. She developed nausea and vomiting, limiting her ability to take oral medications. The family was increasingly distressed.

Our next steps were:

1. Symptom Management: We tried a scopolamine patch for nausea, but it caused dry mouth and dizziness. We then scheduled ondansetron (Zofran) 8 mg every eight hours.
2. Scheduled Non-Opioid Analgesia: We initiated IV acetaminophen at 1000 mg every eight hours on a schedule.
3. Transition to PCA: With her poor oral tolerance, we transitioned her to a morphine Patient-Controlled Analgesia (PCA) pump.

Understanding and Managing a PCA Pump

A PCA pump empowers the patient to self-administer a small dose of IV opioid by pressing a button. You can program it with a basal rate (a continuous hourly infusion) and/or a bolus dose (the amount given with each push).

Many clinicians default to a bolus-only setting. However, if a patient is already on long-acting opioids, their existing requirement can be converted into a basal rate on the PCA. To calculate her starting dose, we converted all her recent opioid use into IV morphine equivalents. Her 24-hour total was 130 mg of oral morphine, which equates to roughly 43.3 mg of IV morphine. We then reduced this by 25% for safety, arriving at a target of about 32.5 mg/24h.

• Basal Rate: We placed half of this into the basal rate, which came to approximately 0.5 mg/hour.
• Bolus Dose: The other half was made available as a bolus dose of 0.5 mg every 15 minutes.

After 24 hours, the data told a story. She had administered 24 successful boluses but had 124 “denied” attempts, meaning she was pushing the button far more often than the lockout interval allowed. Her pain was still a 9/10. Critically, she reported waking up at night in severe pain. This is a key indicator that the basal rate is too low.

We increased the morphine PCA basal rate to 1 mg/hour. However, her pain remained poorly controlled. This reinforced our suspicion of OIH or a lack of efficacy with morphine for her specific pain. She also mentioned that hydromorphone had worked better for her in the past. Listening to the patient is paramount. We performed another opioid rotation, this time from the morphine PCA to a hydromorphone PCA.

Reaching a Diagnosis and Advanced Pain Management

On hospital day 23, a comprehensive evaluation confirmed the pain syndrome was driven by severe, refractory postherpetic neuralgia with prominent central sensitization, significantly worsened by procedural nerve trauma in the T4-T8 distribution. Her functional status was markedly impaired, requiring assistance with most activities due to pain and deconditioning.

Our role then shifted to aggressive symptom management and optimization of comfort and function. For her ongoing nausea and anorexia (exacerbated by pain, medications, and overall illness burden), we started her on dexamethasone. This steroid provides excellent antiemetic effects and has the well-known side effect of increasing appetite, which helped improve her nutritional intake and overall resilience (McGavigan, 2021).

Despite our best efforts—opioid rotations, PCA adjustments, and adjuvants—her pain remained a challenge. Her total MME had climbed to 486 mg/day, yet her relief was minimal. This is where we turned to methadone.

Evidence-Based Opioid Rotation: Why Methadone, When, and How

We turned to methadone only after exhausting other options. It carries unique pharmacological and safety considerations—especially its variable half-life and the risk of QTc prolongation—that demand careful medical oversight. With Dr. Cardenas directing medical safety, we were able to initiate it responsibly.

Methadone’s Pharmacology and Physiology

Methadone is powerful for its dual action.

• It is a racemic mixture. One stereoisomer strongly antagonizes NMDA receptors, mitigating the central sensitization and opioid-induced hyperalgesia our patient was likely experiencing. This is crucial when prior escalations have worsened pain sensitivity.
• As a mu-opioid receptor agonist, it also supports nociceptive pain control.
• It has no toxic metabolites, a benefit in patients with potential renal or hepatic impairment.
• Its high lipophilicity (fat-solubility) facilitates rapid entry into the central nervous system and sustained tissue release, contributing to its long half-life. This necessitates slow titration to avoid accumulation.

Intrathecal Pain Pump: Selection, Physiology, and Dosing

When pain remains intractable—unresponsive to conventional dosing or burdened by unacceptable side effects—we consider an intrathecal pain pump. The patient sought a solution that required less daily management. Intrathecal delivery provides potent analgesia by delivering microdoses directly into the subarachnoid space, acting on spinal pain receptor sites.

The Physiological Advantages:

• Micro-dosing reduces systemic exposure and side effects, particularly advantageous in frail patients. To illustrate, approximately 300 mg of oral morphine is equivalent to just 1 mg delivered intrathecally.
• Direct spinal receptor targeting yields strong relief for dermatomal pain patterns, like our patient’s.
• Hydrophilic opioids like morphine or hydromorphone show greater rostral spread (upward diffusion in the spinal fluid), providing broader coverage from a single injection site.

After extensive goals-of-care conversations, we placed a hydromorphone intrathecal pain pump. This allowed us to wean her off the PCA and begin tapering methadone.

Functional Medicine, Integrative Chiropractic Care, Regenerative PRP Therapy, and Rehabilitation

While these advanced medical interventions were underway, my role as a chiropractor and functional practitioner was to systematically reduce mechanical and inflammatory drivers of pain and support nerve healing.

How Integrative Chiropractic Care Fits

Integrative chiropractic care complements high-dose analgesia by:

• Modulating nociceptive input through targeted joint mobilization, gentle spinal alignment strategies, and soft-tissue techniques. This reduces local inflammatory cytokine release and mechanoreceptor-driven pain signals sent to an already hypersensitive central nervous system.
• Normalizing movement patterns to decrease aberrant loading on inflamed segments. In her case, this meant focusing on gentle thoracic mobilization to improve rib cage mechanics, which were compromised by the chest tube and VATS procedure.
• Breathing and vagal tone strategies, like diaphragmatic breathing, downregulate sympathetic dominance (“fight or flight”) and central sensitization.
• Coordinating with rehabilitation to introduce graded activity, such as improving her ability to sit comfortably for family interactions, which was a key quality-of-life goal.

In patients with high systemic analgesic needs, chiropractic interventions are tailored to avoid provoking pain, focusing on low-amplitude, safe techniques that reinforce functional goals.

Regenerative PRP Therapy Integration

To directly address the peripheral neuropathic component and promote healing of the irritated thoracic nerves and surrounding soft tissues affected by postherpetic neuralgia and procedural trauma, we incorporated ultrasound-guided Platelet-Rich Plasma (PRP) injections. PRP is prepared from the patient’s own blood and is rich in growth factors (including PDGF, TGF-?, VEGF, and others) that support nerve regeneration, reduce neuroinflammation, and enhance repair in areas of chronic irritation or scarring.

In this case, targeted PRP injections were performed in the thoracic paravertebral region corresponding to the T4-T8 dermatomes under ultrasound guidance for precision and safety. This regenerative approach complements pharmacological management and chiropractic care by addressing local tissue and nerve dysfunction at the source, helping to break the cycle of peripheral sensitization that fuels central changes. PRP is particularly valuable in complex neuropathic pain where there is a mix of central sensitization and ongoing peripheral drivers from prior nerve irritation or procedural trauma. We sequenced these injections carefully to avoid interference with other treatments and to support long-term tissue recovery.

Functional Medicine Integration

Functional medicine contributes by targeting biological systems involved in persistent pain:

• Inflammation modulation: We recommended an anti-inflammatory diet rich in omega-3s and ensured she had adequate micronutrient intake, such as magnesium, which helps modulate NMDA receptors.
• Mitochondrial and nerve support: We used nutrients such as CoQ10 and L-carnitine to support cellular energy in her fatigued state, along with consideration of B-vitamins and antioxidants to support nerve health.
• Sleep optimization: We focused on circadian hygiene and minimizing nocturnal pain triggers to improve her resilience.

Dr. Cardenas and I carefully sequenced these strategies to avoid drug-nutrient interactions and respect her fatigue and overall tolerance.

Goals of Care and Holistic Support

After multiple conversations with the patient and family, we focused on comfort, function, and quality of life. Our team provided supportive counseling and emotional/spiritual support to reduce anxiety and pain amplification, which is physiologically tied to central sensitization. Diminished uncertainty and clearer goals help downregulate sympathetic drive and improve pain tolerance.

Outcome:

The patient achieved tolerable pain levels (around 3/10), allowing her to interact meaningfully with family, improve oral intake, rest more comfortably, and gradually increase mobility. The intrathecal pump required only minimal adjustments and provided stable control. With continued outpatient chiropractic care, rehabilitation, and follow-up PRP sessions to support ongoing nerve and tissue healing, she was discharged home with significantly enhanced quality of life and function. Her husband expressed deep gratitude for the combined advanced pain management, regenerative, chiropractic, and supportive interventions that honored her goals and restored comfort during a difficult period.

My clinical observations, shared on platforms like my LinkedIn profile and the Personal Injury Doctor Group, reinforce that complex neuropathic pain demands this level of synchronized, compassionate, multimodal care. It is a dynamic, challenging, and deeply human endeavor that requires persistence, creativity, and a willingness to reassess and adapt our approach constantly. It is in these moments that an integrated team—combining interventional pain strategies, regenerative PRP, chiropractic care, and functional medicine—working in synergy, can provide the most comprehensive care.

References

• Fine, P. G., & Portenoy, R. K. (Eds.). (2019). The ASAM essentials of addiction medicine (3rd ed.). Wolters Kluwer.
• Hanks, G. W., de Stoutz, N. D., & Forbes, K. (1997). The management of pain in cancer. In D. Doyle, G. W. C. Hanks, & N. MacDonald (Eds.), Oxford textbook of palliative medicine (pp. 288-316). Oxford University Press.
• Lee, M., Silverman, S. M., Hansen, H., Patel, V. B., & Manchikanti, L. (2011). A comprehensive review of opioid-induced hyperalgesia. Pain Physician, 14(2), 145–161.
• McGavigan, A. (2021). The use of dexamethasone in palliative care. International Journal of Palliative Nursing, 27(4), 181–186.
• Pasternak, G. W. (2010). Mu-opioid pharmacology: A story of mice and men. Pain, 151(3), 565–569.
• Quill, T. E., & Abernethy, A. P. (2013). General issues in palliative care. In D. L. Longo, A. S. Fauci, D. L.
• Kasper, S. L., Hauser, J. L., Jameson, & J. Loscalzo (Eds.), Harrison’s principles of internal medicine (18th ed., Vol. 1, pp. 88-97). McGraw-Hill.

• Webster, L. R., & Fine, P. G. (2012). Review and critique of opioid rotation practices and associated risks of toxicity. Pain Medicine, 13(4), 562-570.

SEO Tags: Neuropathic Pain, Integrative Medicine, Chiropractic Care, Opioid Rotation, Functional Medicine, Pain Management, El Paso TX, Dr. Alex Jimenez, Complex Pain Case, Multidisciplinary Care, Advanced Pain Management, Postherpetic Neuralgia, Hydromorphone, Pregabalin, Adjuvant Analgesics, Pain Assessment, Opioid-Induced Hyperalgesia, PCA Pump, Central Sensitization, Allodynia, PRP Therapy, Platelet-Rich Plasma, Regenerative Medicine, Ultrasound-Guided PRP, Thoracic Neuropathic Pain, Nerve Regeneration, Post-Procedural Pain, Intrathecal Pain Pump, Dr. Maria Cardenas, Pain Titration, Dexamethasone, NMDA Receptors, Methadone Rotation